Roche Pharmaceutical Development and Sales Overview

Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator Indication Phase/study # of patients 1L ER+/HER2-positive breast cancer (BC) Induction Phesgo plus taxane followed by maintenance with either: ARM A: Giredestrant plus Phesgo Design " ARM B: Phesgo Primary endpoint Status CT Identifier Progression-free survival ■ FPI Q2 2022 Phase III heredERA N=812 NCT05296798 ER-Estrogen receptor; HER2-Human Epidermal growth factor Receptor; Phesgo=FDC of Perjeta and Herceptin for SC administration 115 Roche Oncology

View entire presentation